HNRNPK and melanoma: Collectively, our results demonstrate that the hnRNPK-regulated splicing program represents a novel mechanism driving MAPK pathway inhibitor resistance, providing translational insights for targeting splicing-mediated kinase rewiring in refractory melanoma.